Leonteq Securities AG Invests $1.98 Million in Gilead Sciences, Inc. $GILD

Leonteq Securities AG bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, HoldingsChannel reports. The fund bought 16,102 shares of the biopharmaceutical company’s stock, valued at approximately $1,976,000.

Other large investors have also recently added to or reduced their stakes in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after acquiring an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. increased its position in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after acquiring an additional 7,168 shares during the period. iA Global Asset Management Inc. increased its position in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after acquiring an additional 23,046 shares during the period. Sector Gamma AS increased its position in Gilead Sciences by 15.9% in the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock valued at $16,344,000 after acquiring an additional 20,239 shares during the period. Finally, NewEdge Wealth LLC increased its position in Gilead Sciences by 2.9% in the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after acquiring an additional 17,284 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the topic of several research analyst reports. Morgan Stanley lowered their price target on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target on the stock. Cantor Fitzgerald lowered their price target on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 10th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Stock Up 0.1%

Shares of GILD stock opened at $130.69 on Thursday. The stock has a market cap of $162.26 billion, a PE ratio of 17.81 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The business’s fifty day moving average is $136.86 and its 200-day moving average is $133.57. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead Sciences (GILD) from hold to buy and set a $165 price target, signaling meaningful upside from current levels. Benzinga report on Maxim Group upgrade
• Positive Sentiment: Gilead announced a quarterly dividend of $0.82 per share, reinforcing its appeal as a cash-generating, income-producing biotech with a 2.5% annualized yield.
• Neutral Sentiment: Gilead launched a new $3 billion senior notes offering, which boosts balance-sheet flexibility but also adds to debt financing activity that investors may watch closely. TipRanks article on senior notes
• Neutral Sentiment: Zacks noted that GILD is drawing unusual investor attention, but the item did not include a fresh fundamental catalyst. Zacks trending stock article
• Negative Sentiment: Daiwa Securities trimmed its price target on Gilead to $150 from $161, suggesting some moderation in analyst expectations despite maintaining an outperform rating. MarketScreener report on Daiwa target cut
• Negative Sentiment: Recent insider selling by senior executives, including the CFO, may create a small overhang for sentiment, even though the trades were pre-planned. InsiderTrades report on CFO sale

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock valued at $8,523,570 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.